TURNING POINT THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Turning Point Therapeutics, Inc. - TPTXBusiness Wire • 07/05/22
Bristol-Myers Squibb: Annual Mid Single-Digit Growth Equals Incremental UpsideSeeking Alpha • 06/28/22
U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior TherapyBusiness Wire • 06/24/22
Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple SclerosisBusiness Wire • 06/24/22
New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod)Business Wire • 06/24/22
European Medicines Agency Validates Bristol Myers Squibb's Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line TherapyBusiness Wire • 06/20/22
Bristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs 43rd Annual Global Healthcare ConferenceSeeking Alpha • 06/15/22